What is NON RARE IN EUROPE: Rheumatoid arthritis?
Rheumatoid arthritis (RA) is a long-term autoimmune disease where the body's immune system mistakenly attacks the lining of the joints. This causes painful swelling, stiffness, and damage to the joints over time. Unlike the more common 'wear and tear' arthritis (osteoarthritis), RA is driven by inflammation that can affect many joints at once — most often the hands, wrists, and feet — and can also impact other parts of the body like the lungs, heart, and eyes. The main symptoms include joint pain, swelling, warmth, and morning stiffness that lasts more than an hour. Over time, if not treated, RA can cause permanent joint damage and disability. Many people also feel very tired and generally unwell, especially during flare-ups. The good news is that treatment has improved dramatically in recent decades. There are now many effective medicines available, including disease-modifying antirheumatic drugs (DMARDs) like methotrexate, and newer biologic therapies such as adalimumab, etanercept, and tocilizumab, as well as JAK inhibitors like tofacitinib and baricitinib. With the right treatment plan, many people with RA can live active, fulfilling lives and prevent serious joint damage.
Key symptoms:
Painful, swollen joints — especially in the hands, wrists, and feetMorning stiffness lasting more than one hourWarmth and redness around affected jointsFatigue and low energyFeeling generally unwell or feverishSymmetrical joint involvement (same joints on both sides of the body)Reduced grip strengthSmall lumps under the skin near joints (rheumatoid nodules)Dry eyes or dry mouthShortness of breath (if lungs are affected)Loss of appetite and unintended weight lossDifficulty with everyday tasks like opening jars or buttoning clothes
- Inheritance
- Multifactorial
- Caused by a mix of several genes and environmental factors
- Age of Onset
- Adult
- Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsAesculap AG — NA
Qilu Pharmaceutical Co., Ltd. — PHASE2
Sohag University
Seismic Therapeutic AU Pty Ltd — PHASE1
Changchun GeneScience Pharmaceutical Co., Ltd. — PHASE2
Bursa City Hospital
Tanta University — PHASE4
University Hospital, Brest — NA
Hoffmann-La Roche — PHASE2
Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE1
Data is compiled from FDA regulatory filings and ClinicalTrials.gov, then processed through automated extraction; event classifications and dates may occasionally be misclassified. Verify against the linked FDA filing or trial record before clinical decisions. Updated periodically.
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for NON RARE IN EUROPE: Rheumatoid arthritis.
20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
Specialists
View all specialists →Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
No specialists are currently listed for NON RARE IN EUROPE: Rheumatoid arthritis.
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to NON RARE IN EUROPE: Rheumatoid arthritis.
Community
No community posts yet. Be the first to share your experience with NON RARE IN EUROPE: Rheumatoid arthritis.
Start the conversation →Latest news about NON RARE IN EUROPE: Rheumatoid arthritis
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for NON RARE IN EUROPE: Rheumatoid arthritis.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which joints are affected and how much damage has already occurred?,What treatment do you recommend first, and what are the main side effects I should watch for?,How will we know if the treatment is working, and how long before I should expect to feel better?,What monitoring tests will I need, and how often?,Are there lifestyle changes — like diet, exercise, or stopping smoking — that could help my condition?,What should I do if I have a flare-up between appointments?,Are there any clinical trials or newer treatments I might be eligible for?
Common questions about NON RARE IN EUROPE: Rheumatoid arthritis
What is NON RARE IN EUROPE: Rheumatoid arthritis?
Rheumatoid arthritis (RA) is a long-term autoimmune disease where the body's immune system mistakenly attacks the lining of the joints. This causes painful swelling, stiffness, and damage to the joints over time. Unlike the more common 'wear and tear' arthritis (osteoarthritis), RA is driven by inflammation that can affect many joints at once — most often the hands, wrists, and feet — and can also impact other parts of the body like the lungs, heart, and eyes. The main symptoms include joint pain, swelling, warmth, and morning stiffness that lasts more than an hour. Over time, if not treated,
How is NON RARE IN EUROPE: Rheumatoid arthritis inherited?
NON RARE IN EUROPE: Rheumatoid arthritis follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does NON RARE IN EUROPE: Rheumatoid arthritis typically begin?
Typical onset of NON RARE IN EUROPE: Rheumatoid arthritis is adult. Age of onset can vary across affected individuals.
Are there clinical trials for NON RARE IN EUROPE: Rheumatoid arthritis?
Yes — 20 recruiting clinical trials are currently listed for NON RARE IN EUROPE: Rheumatoid arthritis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Frequently asked questions about NON RARE IN EUROPE: Rheumatoid arthritis
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is NON RARE IN EUROPE: Rheumatoid arthritis?
NON RARE IN EUROPE: Rheumatoid arthritis is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:284130). It is typically inherited as multifactorial. Age of onset is generally adult. For verified primary sources, see the UniteRare NON RARE IN EUROPE: Rheumatoid arthritis page.
How is NON RARE IN EUROPE: Rheumatoid arthritis inherited?
NON RARE IN EUROPE: Rheumatoid arthritis follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.
Are there FDA-approved treatments for NON RARE IN EUROPE: Rheumatoid arthritis?
Approved treatments for NON RARE IN EUROPE: Rheumatoid arthritis are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials recruiting for NON RARE IN EUROPE: Rheumatoid arthritis?
UniteRare currently lists 20 clinical trials relevant to NON RARE IN EUROPE: Rheumatoid arthritis sourced from ClinicalTrials.gov. Each trial entry includes recruitment status, eligibility criteria summary, principal-investigator information, and study locations. Patients should discuss eligibility with their healthcare provider before enrolling.
How do I find a specialist for NON RARE IN EUROPE: Rheumatoid arthritis?
Verified NON RARE IN EUROPE: Rheumatoid arthritis specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.
See full NON RARE IN EUROPE: Rheumatoid arthritis page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.